Research Reports - High plasma adiponectin levels in patients with severe traumatic brain injury
Clin Chim Acta. 2013 Oct 5;427C:37-41
Shen LJ, Yang SB, Lv QW, Zhang GH, Zhou J, Guo M, Huang HB, Li Z, Yang CS
BACKGROUND: Adiponectin plays an important role in the regulation of tissue
inflammation. There is a paucity of data on circulating plasma adiponectin
concentrations in human traumatic brain injury. This study is designed to
investigate the potential associations between plasma adiponectin levels and
clinical outcomes after traumatic brain injury.
METHODS: Plasma adiponectin levels of 86 patients with severe traumatic brain
injury and 86 healthy subjects were determined. Clinical outcomes included
in-hospital mortality, 6-month mortality and 6-month unfavorable outcome (Glasgow
Outcome Scale score of 1-3).
RESULTS: Plasma adiponectin levels were significantly higher in patients compared
to controls (20.5±5.9 vs. 7.7±2.0μg/ml; P<0.001) and emerged as an independent
predictor of in-hospital mortality [odds ratio (OR), 1.318; 95% confidence
interval (CI), 1.049-1.629; P=0.008], 6-month mortality (OR, 1.328; 95% CI,
1.082-1.657; P=0.007) and 6-month unfavorable outcome (OR, 1.240; 95% CI,
1.066-1.443; P=0.005) in a multivariate analysis. For predicting these clinical
outcomes, areas under receiver operating characteristic curve of plasma
adiponectin level were similar to those of Glasgow Coma scale scores (all
P>0.05). However, adiponectin did not improve predictive values of Glasgow Coma
scale scores (all P>0.05).
CONCLUSION: Plasma adiponectin level may represent a novel biomarker for
predicting clinical outcomes of traumatic brain injury.